Navigation Links
Peptimmune Initiates Phase Ib Study of PI-2301 in Multiple Sclerosis Patients and Presentation at BIO 2008
Date:6/17/2008

CAMBRIDGE, Mass., June 17 /PRNewswire/ -- Peptimmune, Inc. a privately held biotechnology company, announced that physicians have treated the first participant in a clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PI-2301 in subjects with Secondary Progressive Multiple Sclerosis (SP-MS). PI-2301 is a novel peptide copolymer for the treatment of multiple sclerosis and other autoimmune diseases.

The Phase Ib multiple-ascending dose, double-blind, placebo-controlled randomized study will involve up to fifty-three subjects with SP-MS who will receive the drug once weekly in four escalating-dose cohorts. Following establishment of safety at potentially therapeutic doses and proof of pharmacologic mechanism, the Company plans to initiate its Phase II study in multiple sclerosis patients in early 2009.

"While the primary goal of this study is to demonstrate safety of PI-2301 in multiple sclerosis patients, we believe that this clinical trial is one of the most comprehensive looks at the pharmacologic effects of any immunomodulator in patients suffering from autoimmune diseases," stated Thomas P. Mathers, President and CEO of Peptimmune. Mr. Mathers will be presenting an overview of the PI-2301 clinical program at the BIO 2008 Business Forum, Wednesday, June 18th, at 9:00 a.m. PDT at the San Diego Convention Center, Room 2.

PI-2301 is a second-generation peptide copolymer from a similar compound class as Copaxone(R) (Teva Pharmaceuticals). PI-2301 works through immune modulation by enhancing the regulatory response of the immune system and thereby controlling the pathogenic autoimmune response observed in some diseases. In a Phase I single ascending dose, double blind placebo controlled randomized study, all doses of PI-2301 were safe and well tolerated, and no serious adverse events were observed. Pharmacodynamic assays demonstrated evidence of immune exposure consistent with the pharmacologic mechan
'/>"/>

SOURCE Peptimmune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Peptimmune Presents Early Clinical Data at European Neurological Society and Federation of Clinical Immunology Societies Meetings
2. Peptimmune Completes Phase I Study with a Novel Peptide Copolymer for the Treatment of Multiple Sclerosis
3. Peptimmune Initiates Phase I Study With a Novel Peptide Copolymer for the Treatment of Multiple Sclerosis
4. Transdel Initiates Ketotransdel(TM) Phase 3 Clinical Program for Pain
5. Medivation Initiates Second Pivotal Phase 3 Trial of Dimebon(TM) in Patients With Alzheimers Disease
6. TorreyPines Therapeutics Initiates Clinical Trial to Evaluate Analgesic Effect of Oral Prodrug of Tezampanel
7. Nuvelo Initiates Phase 1B Clinical Trial of Anticoagulant NU172
8. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
9. Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer
10. Human Genome Sciences Initiates First Clinical Trial of Lead IAP Inhibitor HGS1029 in Advanced Solid Tumors
11. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...PRNewswire/ -- According to Millennium Research Gr...ogy market intelligence, the nearly $3 billion US ...o see rapid growth over the next five years despit...for Trauma Devices 2010 report finds that this ...ve years, with competitors introducing specialized...
(Date:11/25/2009)...nd JOHANNESBURG, November 25 ,iThem...covery announced today,that they have signed a col...ies, services. , Pyxis,s world class comp...ill be coupled with iThemba,s service division to ...to projects identified through Pyxis,internationa...
(Date:11/24/2009)...wire-FirstCall/ -- Endologix, Inc. (Nasdaq: ELGX ...aortic disorders, announced today that it has file... in, the patent infringement lawsuit brought again...s filed in the United States District Court in Ind...that the stay remain in effect while the United St...
Breaking Medicine Technology:US Trauma Fixation Device Market Not Seeing Signs of Slowdown 2US Trauma Fixation Device Market Not Seeing Signs of Slowdown 3iThemba Pharmaceuticals (Pty) Ltd and Pyxis Discovery B.V. Announce Collaborative Agreement to Offer a Combined Service Offering 2Endologix Files Motion to Discontinue Court Proceedings Related to Alleged Patent Infringement 2First Catalog Cancer Biochip for Sequence Capture Now Available from febit 12991 1First Catalog Cancer Biochip for Sequence Capture Now Available from febit 12991 2Elsevier launches official version of BrainNavigator 51462 1Elsevier launches official version of BrainNavigator 51462 2Mystery E coli genes essential for survival of many species 9234 1Mystery E coli genes essential for survival of many species 9234 2
...INESS WIRE)--Mar 26, 2007 - Study results show,tha... (Lp-PLA2), a,cardiovascular-specific inflammatory...ead to heart attack and stroke, is,especially pred...metabolic syndrome--a serious medical condition th...s, which were presented yesterday,at the American ...
...ch 26, 2007 /PRNewswire/ -- Cleveland Clinic,resea...pite raising,high density lipoprotein cholesterol ...did not slow the progression of,plaque buildup in ...und probe. , Steven Nissen, M.D., Chairman of Card...nvestigator of this clinical trial, will,present t...
Other Medicine Technology:Study Presented at the ACC Shows Inflammatory Enzyme Lp-PLA2,Predicts Heart Disease Risk in Metabolic Syndrome Patients 2Study Presented at the ACC Shows Inflammatory Enzyme Lp-PLA2,Predicts Heart Disease Risk in Metabolic Syndrome Patients 3Cholesterol Drug Fails to Slow Progression of Coronary Disease,Cleveland Clinic Study Reports 2Cholesterol Drug Fails to Slow Progression of Coronary Disease,Cleveland Clinic Study Reports 3Cholesterol Drug Fails to Slow Progression of Coronary Disease,Cleveland Clinic Study Reports 4
(Date:11/26/2009)...number of Americans living with diabetes will near... 44.1 million in 2034. Over the same period, spend...13 billion to $336 billion, even with no increase ... the University of Chicago report in the December ...with diabetes covered by Medicare will rise from 8...
(Date:11/26/2009)...n on an emotional rollercoaster, study finds , ...l it the fear factor meets the jubilant sports fan...ecially those who root for the winning team -- enj...tested match and victory was in doubt, producing f...at this Thanksgiving weekend as you,re glued to th...
(Date:11/26/2009)...search Triangle Dental (RTDental), a leading denta...announced the expansion of its services to include...ug Macmillan. , Durham...d to announce that Dr. Doug Macmillan, an experien...itional advanced training seminar. RTDental&rsquo...
(Date:11/25/2009)...v. 25 When most people ... But a chiropractor can also give patients the he...ar Joint, which is where your jaw (mandible) conta..., The most common symptoms associated with TMJ dy...ng of the jaw. But many other symptoms can be cau...
(Date:11/25/2009)...v.25/PRNewswire/-SentinelleMedicalInc.,aleadingman...ftwareandCalgaryScientificInc.,aleadingproviderofs...ionofAegis(TM)Breast4DAdvancedVisualizationsoftwar...o-footprintWebclientbasedmedicalimagingofferingint...owsforzero-footprintaccess-requiringnosoftwaredown...
Breaking Medicine News(10 mins):Health News:Diabetes cases to double and costs to triple by 2034 2Health News:Diabetes cases to double and costs to triple by 2034 3Health News:Watching the Nail-Biting Big Game Hurts So Good 2Health News:Watching the Nail-Biting Big Game Hurts So Good 3Health News:Dr. Douglas Macmillan Now Providing LUMINEERS at Research Triangle Dental 2Health News:Sentinelle Medical Inc. Introduces Aegis(TM) Web Powered By Calgary Scientific's PureWeb Technology 2Health News:Sentinelle Medical Inc. Introduces Aegis(TM) Web Powered By Calgary Scientific's PureWeb Technology 3
... was initiated by Quebec Health Minister Philippe ...e option of private health-care insurance //. ... struck down Quebec's ban on private insurance, on...he development of Bill 33, proposed by Couillard, ...
...madoss Friday warned of "strong action" against "i...l India Institute of Medical Sciences// (AIIMS), s...tion into a "political hub". "Some people hav...idelines of a medical seminar here. Describ...
...Jonas Frisén who is at the Karolinska Institutet t...ew cells are being produced// by individual intest...hed in the journal Cell. The research feels that t...nually being replaced by new. If too many new cell...
...a report www.bmj.com which speaks of the enhanced ...women with diabetes. // They have cautioned that w... suffering diabetes shows no improvement. Res... delivered between 1 March 2002 and 28 February 20...
...ost Common Human Disease Tooth, decay,prevalent,d...ral health,stress,Few are aware that tooth decay ... or that there's a new approach to repairing den...ion which will be presented when the International...
... boy’s divorced parents, whether to circumcise the... a painful inflammation in last year, his mother n... dad argues that he is fine and if circumcision wa...umcision to his father. The mother's attorne...
Other Medicine News:Health News:Quebecers To Choose Private Health-Care Insurance 2Health News:Mechanism of Stem Cell Regulation Identified 2Health News:Diabetic women may suffer a complicated pregnancy 2Health News:Tooth Deccay is Still The Most Common Human Disease 2Health News:Tooth Deccay is Still The Most Common Human Disease 3Health News:Tooth Deccay is Still The Most Common Human Disease 4
...iratory Products, ,Westmed designs, manufacturers...nesthesia and Respiratory professionals. Our missi...nce the clinician's ability to deliver quality med...om line. , ,Our web site is designed with our cus...
...iratory Products, ,Westmed designs, manufacturers...nesthesia and Respiratory professionals. Our missi...nce the clinician's ability to deliver quality med...om line. , ,Our web site is designed with our cus...
...lizer achieves optimum lung penetration for maximu...ze range is 1.04-1.10 µ at 6-8 LPM. Latex-fr...t., ,As the world leader in airway management pro...rance of proven technology by offering top brands ...
...lizer achieves optimum lung penetration for maximu...ze range is 1.04-1.10 µ at 6-8 LPM. Latex-fr...t., ,As the world leader in airway management pro...rance of proven technology by offering top brands ...
Medicine Products: